The ACCOLADE study on C3 glomerulopathy
The selective C5a receptor inhibitor avacopan could be used in future to treat immune-mediated inflammatory disorders in C3G renal disease. C3 glomerulopathy is a rare disease in which the deposition of C3 protein causes severe inflammation of the glomeruli, which can progress to end stage kidney disease requiring dialysis or transplantation. A new study […]
Continue Reading